April 3, 2020 The President and CEO of the LRA, Kenneth Farber wrote personally to Speaker Nancy Pelosi and Leader Kevin McCarthy in the House of Representatives and Leader Mitch McConnell and Leader Chuck Schumer in the Senate asking that “any COVID-19 response and recovery package include provisions to ensure lupus patients maintain access to […] READ MORE
April 1, 2020 An investigational treatment, iguratimod showed positive results in an early clinical study of people with lupus nephritis that is refractory, meaning it has stubbornly resisted previous treatment with at least two immunosuppressants. Results were reported in Arthritis Research & Therapy. The small study included 14 patients with refractory lupus nephritis. Each were […] READ MORE
April 1, 2020 Thirteen new applications for promising scientific studies were just recommended for funding through the Lupus Research Program (LRP) within the Department of Defense! The $5 million in awards for Fiscal Year 2019 brings the total to $15 million over three years. The dedicated Lupus Research Program was first established in 2017 under […] READ MORE
March 31, 2020 A statement issued March 29 by the U.S. Department of Health and Human Services (HHS) announced that millions of donated doses of hydroxychloroquine sulfate and chloroquine phosphate had been accepted into the Strategic National Stockpile. In addition, the statement announced that the Food and Drug Administration has granted Emergency Use Authorization (EUA) […] READ MORE
March 30, 2020 The rheumatology community has been in discussions with the U.S. Food and Drug Administration and many pharmaceutical companies about the potential shortage of hydroxychloroquine (brand name Plaquenil) in the COVID-19 epidemic, and we are seeing much progress to increase its production and availability. The LRA especially thanks Sandoz, the generics division of […] READ MORE
26 de marzo de 2020 La Alianza para la investigación de Lupus (LRA), la principal organización de investigación del mundo dedicada a la investigación del lupus, continúa observando rápidamente los cambios en relación con la COVID-19 y está controlando de cerca las políticas y acciones del gobierno federal, las agencias de atención médica, las organizaciones […] READ MORE
March 26, 2020 The Lupus Research Alliance (LRA), the world’s leading research organization dedicated to lupus research, continues to watch rapidly changing developments regarding COVID-19 and is closely monitoring the policies and actions of the federal government, healthcare agencies, medical organizations and the pharmaceutical industry on behalf of people with lupus. Thrust into the spotlight […] READ MORE
March 26, 2020 CVS put out the following statement yesterday assuring its clients that the company is protecting a supply for people already taking hydroxychloroquine. CVS Health helping protect supply of medicines potentially useful for COVID-19 treatment CVS Caremark, the pharmacy benefit management business of CVS Health, is working with clients to implement new measures […] READ MORE
March 25, 2020 LRA Sponsors COVID-19 Global Rheumatology Alliance The LRA is proud to be among the sponsors of the COVID-19 Global Rheumatology Alliance, a grassroots group led by rheumatologists and uniting rheumatologists and patients with rheumatic diseases worldwide to respond to the global pandemic. In concert with the American College of Rheumatology, the group’s […] READ MORE
19 de marzo de 2020 En diciembre de 2019, se identificó un nuevo virus llamado SARS-COV-2 en Wuhan, China. Se descubrió que este virus causaba una enfermedad respiratoria grave en los pacientes, el cual posteriormente recibió el nombre del tipo de virus que provocaba la enfermedad y el año en que se identificó (enfermedad por […] READ MORE
March 19, 2020 In December 2019, a new virus called SARS-COV-2 was identified in Wuhan, China. This virus was found to cause a severe respiratory illness in patients which was later named after the type of virus that caused it and the year it was identified (coronavirus disease 2019 or COVID-19)1 Currently there is no […] READ MORE
18 de marzo de 2020 Estimados amigos: Su bienestar es la máxima prioridad para todos nosotros en la Alianza para la investigación de Lupus (Lupus Research Alliance, LRA). Estamos consultando a los mejores clínicos y científicos especializados en lupus para supervisar la situación planteada por la propagación del coronavirus SARS (SARS-CoV-2), comúnmente denominado COVID-19, en […] READ MORE
